ChromaDex shares have risen over 130% since my original Seeking Alpha article. Since then a new development has occurred that could be very positive for shareholders.
In a study published Thursday in the journal Cell, researchers from Harvard Medical School identified a breakdown in cell communication in animals that causes aging to accelerate. This is important for ChromaDex because this study suggested that increasing NAD could reverse the aging process.
When the researchers looked at the muscle from 2-year-old mice that had been given a compound that increased NAD, they found that in three indicators of aging (insulin resistance, inflammation and muscle wasting), the tissue in the mice looked like that of 6-month old mice.
In humans, that would be like the muscle of a 60-year-old transforming into the muscle of a 20-year-old, according to the researchers.
What's important for ChromaDex is that the company appears to have the only oral compound, Niagen, that is capable of boosting NAD. In the Harvard study, scientists used a compound that needed to be injected, which would not be practical commercially.
Here is a link with more information on this Harvard study.
Disclosure: I am long OTC:CDXC.